Warp Sciences Raises $215 Million, Led by Lightspeed, for a Robot-Assisted Chemistry Lab

Warp Sciences, a chemistry contract research startup run by former OpenAI product chief Kevin Weil, came out of stealth on Oct. 22 with a $215 million Series A led by Lightspeed. TechCrunch reported a valuation of $865 million, a figure it attributed to Weil.

The money was announced as closed, not as a target, and the company's release gives no valuation of its own. That leaves the $865 million as one person's number on a company that has named no customer. If it is post-money, the new cash is about 25 percent of the company. If it is pre-money, the stake falls to about 20 percent, so the figure that travels depends on a word the announcement never uses.

What Warp Sciences sells, and what it does not

Warp is building a U.S.-based chemistry contract research organization, a lab that makes molecules for other companies' drug programs. Its first service is lead optimization analog synthesis, which means making many small variations of a promising compound so researchers can compare them. The release says Warp has no drug pipeline of its own.

TechCrunch, in a report by Marina Temkin, described the pitch as reshoring work that biotech companies have outsourced to contractors in China such as WuXi AppTec. It said human chemists wear cameras and sensor gloves to train the robots. The release lists early hires with robotics experience from Genesis, Skild AI and 1X, and scientific backgrounds from Genentech and Lawrence Livermore National Laboratory.

Neither document gives a headcount, a lab address, a price per compound, a turnaround time or a date for the first customer delivery.

The founders and the investor list

The release names four founders.

Founder	Title at Warp	Previous role named in release
Kevin Weil	Chief executive	OpenAI chief product officer and VP of Science
Sol Reisberg	Chief scientific officer	Medicinal chemistry leadership, Terremoto Biosciences
DJ Patil	Chief operating officer	First U.S. Chief Data Scientist, White House; Devoted Health
Mano Paluri	Chief technology officer	VP at Meta Superintelligence Labs; FAIR founding member

Lightspeed led. IVP, Mayfield, Lux Capital, Premji Invest and Menlo Ventures took part, according to TechCrunch, and the release adds more than a dozen further funds and a list of angels. Brian Armstrong, Mike Krieger and Dylan Field are among the named individuals.

Patil's line in the release is the clearest statement of the business: "We're not developing drugs of our own. We're building the infrastructure for the people who do." A service company with no pipeline earns per order rather than on a drug's success, so the comparison that matters is with existing chemistry providers, not with drug developers. The release does not name one.

How it compares with this week's other large rounds

Warp is not the only robotics-adjacent raise The Terminal has covered this month. Eka Robotics sold about 10 percent for $150 million, and Warhound raised $200 million before it had bred the animals it plans to clone. Warp's round is larger than either, and it arrives with a founding team's résumés rather than a service customers can order.

The checkable next step is a first named customer or a lab address. Until the company publishes either, the $865 million remains a figure from a founder's post, repeated by one outlet.